ABNORMALLY HIGH CIRCULATION LEVELS OF TISSUE-PLASMINOGEN ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN PATIENTS WITH A HISTORY OF ISCHEMIC STROKE

被引:94
|
作者
MARGAGLIONE, M
DIMINNO, G
GRANDONE, E
VECCHIONE, G
CELENTANO, E
CAPPUCCI, G
GRILLI, M
SIMONE, P
PANICO, S
MANCINI, M
机构
[1] UNIV NAPLES,MED CLIN,IST MED INTERNA & MALATTIE DISMETAB,I-80131 NAPLES,ITALY
[2] IRCCS,UNITA TROMBOSI & ATEROSCLEROSI,SAN GIOVANNI ROTO,ITALY
来源
ARTERIOSCLEROSIS AND THROMBOSIS | 1994年 / 14卷 / 11期
关键词
FIBRINOLYSIS; STROKE; RISK FACTORS;
D O I
10.1161/01.ATV.14.11.1741
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We evaluated 106 subjects with and 109 subjects without a history of ischemic stroke. All were attending a metabolic ward. The two groups were compared for major risk factors for ischemic events. A positive family history for ischemic complications of atherosclerosis was more common in subjects with a history of stroke than in those without; moreover, plasma levels of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (TPA) were higher in patients with documented previous events. A strong positive significant correlation was found between TPA and PAI-1 levels, and an interaction between age and TPA was observed when the sample was stratified according to ages being above or below 70 years. When the patient population was analyzed according to the number of ischemic events, it was found that 62 of the 106 subjects with a history of stroke had experienced more than one ischemic event. Under these conditions, the levels of TPA and PAI-1 still correlated with the occurrence of previous ischemic episodes. As in the whole patient sample, TPA was the strongest discriminator. We conclude that in subjects attending a metabolic ward, TPA and PAI-1 levels consistently help identify subjects with a history of cerebral ischemic episodes and that TPA is the strongest discriminator.
引用
收藏
页码:1741 / 1745
页数:5
相关论文
共 50 条
  • [21] GENE INACTIVATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICE
    CARMELIET, P
    SCHOONJANS, L
    STASSEN, JM
    KIECKENS, L
    VANNUFFELEN, A
    DEMOL, M
    COLLEN, D
    MULLIGAN, R
    [J]. THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 764 - 764
  • [22] TISSUE-PLASMINOGEN ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITOR AND RISK OF PERIPHERAL ARTERIAL-DISEASE
    SMITH, FB
    LEE, AJ
    RUMLEY, A
    FOWKES, FGR
    LOWE, GDO
    [J]. ATHEROSCLEROSIS, 1995, 115 (01) : 35 - 43
  • [23] Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity
    Umpaichitra, V
    Hussain, MM
    Castells, S
    [J]. PEDIATRIC RESEARCH, 2005, 58 (03) : 483 - 487
  • [24] Plasminogen Activator Inhibitor-1 and Tissue-Plasminogen Activator in Minority Adolescents with Type 2 Diabetes and Obesity
    Vatcharapan Umpaichitra
    M Mahmood Hussain
    Salvador Castells
    [J]. Pediatric Research, 2005, 58 : 483 - 487
  • [25] HEPATIC-CLEARANCE OF COMPLEXES OF TISSUE-PLASMINOGEN ACTIVATOR WITH C1-INHIBITOR AND PLASMINOGEN-ACTIVATOR INHIBITOR
    PINCHES, SA
    COMBE, CJ
    BOOTH, NA
    [J]. THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1004 - 1004
  • [26] PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND ATHEROTHROMBOSIS
    JUHANVAGUE, I
    ALESSI, MC
    [J]. THROMBOSIS AND HAEMOSTASIS, 1993, 70 (01) : 138 - 143
  • [27] CIRCADIAN FLUCTUATIONS OF TISSUE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 ANTIGENS IN VASOSPASTIC ANGINA
    SAKATA, K
    HOSHINO, T
    YOSHIDA, H
    ONO, N
    OHTANI, S
    YOKOYAMA, S
    MORI, N
    KABURAGI, T
    KURATA, C
    URANO, T
    TAKADA, Y
    TAKADA, A
    [J]. AMERICAN HEART JOURNAL, 1992, 124 (04) : 854 - 860
  • [28] TISSUE-PLASMINOGEN ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITORS, AND ACTIVATOR-INHIBITOR COMPLEX IN LIVER-DISEASE
    LEIPER, K
    CROLL, A
    BOOTH, NA
    MOORE, NR
    SINCLAIR, T
    BENNETT, B
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1994, 47 (03) : 214 - 217
  • [29] VITRONECTIN GOVERNS THE INTERACTION BETWEEN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    KEIJER, J
    EHRLICH, HJ
    LINDERS, M
    PREISSNER, KT
    PANNEKOEK, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (16) : 10700 - 10707
  • [30] EFFECTS OF DIPYRAMIDOLE AND PROSTAGLANDIN-E1 ON PLASMA-LEVELS OF TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN CARDIAC PATIENTS
    HUBER, K
    BECKMANN, R
    PACHER, R
    RIMPFL, T
    WOITA, J
    BINDER, BR
    [J]. THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1365 - 1365